本妥昔单抗维达汀联合苯达莫司汀治疗难治性或复发性霍奇金淋巴瘤。一项回顾性真实世界研究。
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
机构信息
Department of Oncology, Hematology and BMT Unit, Casa di Cura La Maddalena, Palermo, Italy.
Division of Hematology, AOU Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
出版信息
Eur J Haematol. 2020 Jun;104(6):581-587. doi: 10.1111/ejh.13400. Epub 2020 Mar 13.
OBJECTIVE AND METHODS
In order to assess the efficacy of brentuximab vedotin (Bv) in combination with bendamustine (B) in multiple relapsed or refractory (RR) classic Hodgkin lymphoma (cHL), medical records of 47 patients treated with BvB in second relapse or beyond were reviewed.
RESULTS
The median number of previous treatments was 2 (1-4). Bv was given at 1.8 mg/kg on day 1 and bendamustine at 90 mg/m on days 1 and 2 of a 21-day cycle. The median number of BvB cycles was 4 (2-7), and all patients were evaluable for efficacy. The CR and OR rates were 49% and 79%, respectively; 67% of responding patients and 2 in stable disease proceeded to a SCT procedure. After a median follow-up of 19 months (5-47), median PFS was 18 months (95%CI: 23-29), and the 2-year OS was 72%. Significantly longer PFS and OS were observed in patients attaining a major clinical response to treatment and in those who received consolidation with SCT. Fifteen (32%) patients experienced severe (G > 2) toxicity. The main toxicities were neutropenia (23%), gastrointestinal (10%), peripheral sensory neuropathy (11%), and infection (4%).
CONCLUSION
Our real-world results suggest that BvB is an effective third-line rescue and bridge-to-transplant regimen for RR-cHL patients.
目的和方法
为了评估 Brentuximab vedotin（Bv）联合苯达莫司汀（B）在多种复发或难治性（RR）经典霍奇金淋巴瘤（cHL）中的疗效，我们回顾了 47 例接受 BvB 二线以上复发治疗的患者的病历。
结果
中位既往治疗数为 2（1-4）。Bv 于第 1 天以 1.8mg/kg 给药，苯达莫司汀于第 1 天和第 2 天以 90mg/m2 给药，21 天为一个周期。BvB 周期的中位数为 4（2-7），所有患者均可进行疗效评估。完全缓解率（CR）和客观缓解率（OR）分别为 49%和 79%；67%的缓解患者和 2 例稳定疾病患者继续进行 SCT 治疗。中位随访 19 个月（5-47）后，中位无进展生存期（PFS）为 18 个月（95%CI：23-29），2 年总生存率（OS）为 72%。获得主要临床缓解的患者和接受 SCT 巩固治疗的患者，PFS 和 OS 明显延长。15 例（32%）患者发生严重（G>2）毒性。主要毒性为中性粒细胞减少（23%）、胃肠道（10%）、周围感觉神经病变（11%）和感染（4%）。
结论
我们的真实世界研究结果表明，BvB 是 RR-cHL 患者有效的三线挽救和桥接移植方案。
Zotero 插件